The Vanguard Group 13D and 13G filings for Mirati Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
2024-02-13 5:09 pm Purchase |
2023-12-29 | 13G | Mirati Therapeutics, Inc. MRTX |
The Vanguard Group | 5,306,693 7.570% |
332,805![]() (+6.69%) |
Filing |
2023-02-09 11:27 am Purchase |
2022-12-30 | 13G | Mirati Therapeutics, Inc. MRTX |
The Vanguard Group | 4,973,888 8.640% |
534,911![]() (+12.05%) |
Filing |
2022-02-10 08:27 am Purchase |
2021-12-31 | 13G | Mirati Therapeutics, Inc. MRTX |
The Vanguard Group | 4,438,977 8.040% |
406,739![]() (+10.09%) |
Filing |
2021-02-10 11:28 am Purchase |
2020-12-31 | 13G | Mirati Therapeutics, Inc. MRTX |
The Vanguard Group | 4,032,238 7.920% |
964,627![]() (+31.45%) |
Filing |